JP2005524657A - 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法 - Google Patents

治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法 Download PDF

Info

Publication number
JP2005524657A
JP2005524657A JP2003570887A JP2003570887A JP2005524657A JP 2005524657 A JP2005524657 A JP 2005524657A JP 2003570887 A JP2003570887 A JP 2003570887A JP 2003570887 A JP2003570887 A JP 2003570887A JP 2005524657 A JP2005524657 A JP 2005524657A
Authority
JP
Japan
Prior art keywords
composition
acid
carrier
term
metal ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003570887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524657A5 (enExample
Inventor
イライジャ， エム． ボロティン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmain Corp
Original Assignee
Pharmain Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp filed Critical Pharmain Corp
Publication of JP2005524657A publication Critical patent/JP2005524657A/ja
Publication of JP2005524657A5 publication Critical patent/JP2005524657A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
JP2003570887A 2002-02-27 2003-02-27 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法 Pending JP2005524657A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36035002P 2002-02-27 2002-02-27
PCT/US2003/005937 WO2003072143A1 (en) 2002-02-27 2003-02-27 Compositions for delivery of therapeutics and other materials, and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2005524657A true JP2005524657A (ja) 2005-08-18
JP2005524657A5 JP2005524657A5 (enExample) 2006-04-13

Family

ID=27766225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570887A Pending JP2005524657A (ja) 2002-02-27 2003-02-27 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法

Country Status (8)

Country Link
US (2) US7138105B2 (enExample)
EP (1) EP1478406B1 (enExample)
JP (1) JP2005524657A (enExample)
AT (1) ATE494010T1 (enExample)
AU (1) AU2003219922B2 (enExample)
CA (1) CA2476589C (enExample)
DE (1) DE60335608D1 (enExample)
WO (1) WO2003072143A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520040A (ja) * 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
JP2010510248A (ja) * 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
JP2010530415A (ja) * 2007-06-21 2010-09-09 ファーマイン コーポレーション 治療薬及び他の物質の送達のための組成物
JP2010535714A (ja) * 2007-08-03 2010-11-25 ファーマイン コーポレーション 長期間作用性ペプチド類似体のための組成物
JP2022537337A (ja) * 2019-06-18 2022-08-25 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
JP2023525544A (ja) * 2020-05-12 2023-06-16 ビーエーエスエフ ソシエタス・ヨーロピア 分散剤としてのリジンのカルボキシメチル化ポリマーの使用及びそれを含む組成物

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN1649628A (zh) * 2002-02-26 2005-08-03 天藤制药株式会社 向脂质体中包封金属络合物的方法
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US20100069293A1 (en) * 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7629049B2 (en) * 2002-10-18 2009-12-08 Medasorb, Inc. Hemocompatible polymer systems and related devices
EP1659143A4 (en) * 2003-07-28 2008-10-08 Teijin Ltd HYDROGEL SENSITIVE AT TEMPERATURE
JP2007500027A (ja) * 2003-07-30 2007-01-11 アンタイス エス．エイ． 生物医学的な使用のための複合マトリックス
EP1663186B1 (en) * 2003-09-10 2007-06-20 Cristália Produtos Químicos Farmacêuticos Ltda. Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
EA018643B1 (ru) * 2004-02-23 2013-09-30 Цайтэн Чжан Раствор металлсодержащего хелатного полимера и его применение (варианты)
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
PT2985039T (pt) * 2004-03-03 2018-11-09 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
BRPI0404983A (pt) * 2004-09-03 2006-05-02 Nanocore Biotecnologia Ltda composições imunogênicas
EP1846042A2 (en) * 2005-01-05 2007-10-24 Board of Regents, The University of Texas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20090291508A1 (en) * 2008-05-20 2009-11-26 Rapid Pathogen Screening Inc. Nanoparticles in diagnostic tests
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE502006007526D1 (de) * 2005-09-09 2010-09-09 Aesculap Ag Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
JP5623016B2 (ja) 2005-12-01 2014-11-12 プロネイ・セラピューティクス・インコーポレイテッドＰｒｏｎａｉｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌治療法およびそれに用いる医薬組成物
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US9604196B2 (en) 2006-11-20 2017-03-28 Cytosorbent, Inc. Size-selective hemocompatible polymer system
EP2500015A1 (en) * 2006-12-05 2012-09-19 Landec Corporation Delivery of drugs
US20100004124A1 (en) * 2006-12-05 2010-01-07 David Taft Systems and methods for delivery of materials for agriculture and aquaculture
US8399007B2 (en) * 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US20090263346A1 (en) * 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
US20090246155A1 (en) * 2006-12-05 2009-10-01 Landec Corporation Compositions and methods for personal care
WO2008128058A1 (en) * 2007-04-13 2008-10-23 The Trustees Of The University Of Pennsylvania New gallium bisaminothiolate complexes for myocardial imaging
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US9095568B2 (en) * 2007-09-26 2015-08-04 Mark Berninger Therapeutic and vaccine polyelectrolyte nanoparticle compositions
US8114883B2 (en) * 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
EP2341905B2 (en) * 2008-09-04 2023-09-13 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
KR101724171B1 (ko) 2009-09-09 2017-04-06 파마인 코포레이션 치료제 전달용 음이온-코어 조성물, 및 이를 제조 및 사용하는 방법
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
DK2343051T3 (da) 2010-01-05 2014-10-27 Nat Univ Dong Hwa Anti-cancer formulering
GB2490084A (en) * 2010-02-22 2012-10-17 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
US8785569B2 (en) * 2011-11-22 2014-07-22 Original Biomedicals Co., Ltd. Drug carrier with chelating complex micelles and the application thereof
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3198021B1 (en) 2014-09-24 2020-12-16 Colgate-Palmolive Company Bioavailability of metal ions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN105054074A (zh) * 2015-07-01 2015-11-18 浙江海洋学院 一种鱼糜酶解肽亚铁螯合物抗氧化微胶囊及其制备工艺
AU2016335866B2 (en) 2015-10-09 2021-02-11 Christine Jane ALLEN Crosslinked particles
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11905377B2 (en) 2019-01-17 2024-02-20 Pendant Biosciences, Inc. Factors controlling drug release in cross-linked poly(valerolactone) based matrices
WO2025207519A1 (en) * 2024-03-23 2025-10-02 Texas Tech University System Biocompatible and biodegradable polymer nanodiscs as lipoprotein-mimicking nanocarriers with high stability and long circulation time for drug delivery

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5776894A (en) 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US5554388A (en) 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
JPH08501097A (ja) * 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
IL112920A (en) 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5929031A (en) 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) * 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JPH10158195A (ja) * 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
GEP20022707B (en) 1997-07-18 2002-06-25 Infimed Inc Us Biodegrading Macromers for the Controlled Release of Biologically Active Substances
DE19740069A1 (de) * 1997-09-12 1999-03-18 Clariant Gmbh Mischungen von langkettigen Phosphorsäurealkylestern
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
ES2335066T3 (es) 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
ES2284266T3 (es) * 1998-08-12 2007-11-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composiciones terapeuticas liposomicas que se pueden obtener mediante el uso de un grandiente de sulfato amonico.
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
BR0008590A (pt) * 1999-01-08 2001-10-30 Emisphere Tech Inc Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
WO2000065352A1 (en) 1999-04-28 2000-11-02 Eidgenossisch Technische Hochschule Zurich Polyionic coatings in analytic and sensor devices
CA2386626A1 (en) 1999-10-15 2001-04-26 Richard Murphy Targeted vectors
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2001252201A1 (en) 2000-03-14 2001-09-24 Amylin Pharmaceuticals, Inc. Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
CN1462191B (zh) 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
EP2364734B1 (en) 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040092432A1 (en) 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
AU775663B2 (en) 2000-10-20 2004-08-12 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
EP1215501A1 (en) * 2000-11-30 2002-06-19 Molecular Devices Corporation Use of a poly(amino-acid)-metal ion complex to link a label to a species of interest
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
WO2003018516A2 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2003028626A2 (en) 2001-10-01 2003-04-10 Eli Lilly And Company Glucagon-like peptides (glp-1) and treatment of respiratory distress
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CN1596120A (zh) 2001-11-26 2005-03-16 第一三得利制药株式会社 经鼻吸收用药物组合物
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2005524657A (ja) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
EP1539210A4 (en) 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
BRPI0408925A (pt) 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
JP4936884B2 (ja) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7521527B2 (en) 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
FR2867679B1 (fr) 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
CA2564780C (en) 2004-04-20 2010-11-23 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
US7285529B2 (en) 2005-02-28 2007-10-23 Gene Tools, Llc Embedder compositions and methods for detecting and killing cells in acidic areas of tumors
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20100041612A1 (en) 2005-09-08 2010-02-18 Martin Beinborn Fragments of the Glucagon-Like Peptide-1 and Uses Thereof
WO2007048190A1 (en) 2005-10-25 2007-05-03 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
EP3095456A1 (en) 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
AU2006336176B2 (en) 2006-01-20 2013-08-22 Starpharma Pty Limited Modified macromolecule
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507248B2 (en) 2005-12-19 2019-12-17 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2014132036A (ja) * 2005-12-19 2014-07-17 Pharmain Corp 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
US9737615B2 (en) 2005-12-19 2017-08-22 PharmalN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2009520040A (ja) * 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
JP2010510248A (ja) * 2006-11-21 2010-04-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分をターゲティング部分と組み合わせて使用する金属酸化還元酵素阻害剤
JP2010530415A (ja) * 2007-06-21 2010-09-09 ファーマイン コーポレーション 治療薬及び他の物質の送達のための組成物
JP2010535714A (ja) * 2007-08-03 2010-11-25 ファーマイン コーポレーション 長期間作用性ペプチド類似体のための組成物
JP2014062127A (ja) * 2007-08-03 2014-04-10 Pharmain Corp 長期間作用性ペプチド類似体のための組成物
JP2014062128A (ja) * 2007-08-03 2014-04-10 Pharmain Corp 長期間作用性ペプチド類似体のための組成物
JP2015110662A (ja) * 2007-08-03 2015-06-18 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 長期間作用性ペプチド類似体のための組成物
JP2022537337A (ja) * 2019-06-18 2022-08-25 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
JP2022537331A (ja) * 2019-06-18 2022-08-25 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
JP7691701B2 (ja) 2019-06-18 2025-06-12 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
JP2023525544A (ja) * 2020-05-12 2023-06-16 ビーエーエスエフ ソシエタス・ヨーロピア 分散剤としてのリジンのカルボキシメチル化ポリマーの使用及びそれを含む組成物

Also Published As

Publication number Publication date
US7790140B2 (en) 2010-09-07
US7138105B2 (en) 2006-11-21
AU2003219922A1 (en) 2003-09-09
CA2476589C (en) 2014-02-25
US20060239924A1 (en) 2006-10-26
ATE494010T1 (de) 2011-01-15
US20030224974A1 (en) 2003-12-04
AU2003219922B2 (en) 2009-09-10
DE60335608D1 (de) 2011-02-17
WO2003072143A1 (en) 2003-09-04
EP1478406A4 (en) 2006-01-11
EP1478406A1 (en) 2004-11-24
WO2003072143A9 (en) 2004-03-04
CA2476589A1 (en) 2003-09-04
EP1478406B1 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
JP2005524657A (ja) 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US7589169B2 (en) Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US8231859B2 (en) Compositions for delivery of therapeutics and other materials
JP5600846B2 (ja) キトサン基材高分子接合体及びその製造方法
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
CN105188764B (zh) Dna嵌入剂的细胞递送
Gao et al. Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting
JP5692887B1 (ja) ポリマーミセル医薬組成物
JP2020535171A (ja) 去勢抵抗性前立腺癌
JP7069135B2 (ja) アルブミンベースのナノ医薬品を使用するための組成物及び方法
JP7644105B2 (ja) 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム
CN114392358A (zh) 一种肿瘤靶向的核酸适体药物偶连物
US20240261390A1 (en) Vaccine for prevention or treatment of viral infection
EP4349869A1 (en) Vaccine for prevention or treatment of viral infection
CN113350531A (zh) 前列腺特异性膜抗原结合配体偶联物及其应用
Pathak et al. Avidin-based nanoparticles for drug delivery
WO2025206037A1 (ja) ポリロタキサン、それを含む複合体、それを含む医薬組成物、及び、上記複合体の製造方法
Hincapie Protein Nanoparticles for Applications in Chemical Biology and Immunology
Pan Development of a Cationic Mucic Acid Polymer-Based Nanoparticle siRNA Delivery System
CN101044241A (zh) 用于将选择的分子转运至细胞的载体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060223

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20080313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080314

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20080627

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20080725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100924

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100924

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111109